In absolute terms, tirzepatide users lost an average of 22.8kg (about 50 pounds) compared to 15.0kg (about 33 pounds) with semaglutide
[7] [8] Certain probiotic strains have clinical evidence for constipation relief
This should include: Comprehensive medication review : Documenting all prescribed medications, over-the-counter products, and supplements to identify potential interactions, particularly noting fluoxetine's strong CYP2D6 inhibition Mental health evaluation : Assessing depression severity, suicide risk, and treatment response to fluoxetine Weight and metabolic parameters : Recording baseline weight, BMI, waist circumference, blood pressure, and relevant blood tests (HbA1c, lipid profile, liver function) Renal function and electrolytes : Particularly sodium levels, given the risk of SSRI-induced hyponatraemia Cardiovascular assessment : Particularly important given semaglutide's potential effects on heart rate Gastrointestinal and gallbladder history : Identifying pre-existing conditions that might be exacerbated Ophthalmological assessment : For patients with diabetes, as rapid improvement in glycaemic control may worsen diabetic retinopathy Ongoing monitoring should occur at regular intervals, typically: Monthly initially : During Wegovy dose escalation (following the standard titration schedule from 0.25 mg to 2.4 mg over 1620 weeks) Every 36 months : Once stable doses are achieved, monitoring weight, mental health status, side effects, and treatment adherence As clinically indicated : More frequent review if concerns arise Dose adjustments may be necessary based on individual response
GLP-1 receptor agonists caused thyroid C-cell tumors in rodent studies at all dose levels tested (Wegovy prescribing information, Novo Nordisk, 2021)
Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity
